Table 3 Ten year CFFS for patients with low or high levels of ERα in TS and aromatase in TE respectively in relation to prognostic groups of PCa.

From: Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome

Risk groups of localized prostate cancer

10 year CFFS (%)

ERα in TS

Aromatase in TE

Low (%)

High (%)

p

Low (%)

High (%)

p

I (n = 42)

NE

NE

—

NE

NE

—

IIA (n = 109)

92

96

0.886

92

96

0.904

IIB (n = 206)

87

99

0.001

93

97

0.148

III (n = 154)

76

84

0.442

76

88

0.074

  1. The stratification of our cohort into prognostic groups are constructed according to the American Joint Committee on Cancer (AJCC) TNM system. By adding either the ERα or the aromatase marker to the already well-established clinical markers, prognostic impact is added across each pathological stage (univariate analysis; log rank test), significant p-values in bold (threshold p ≤ 0.05). Prognostic group IV has been removed due to n = 0.
  2. Abbreviations: PCa = prostate cancer; ERα = Estrogen receptor α; TS = tumor associated stroma; TE = Tumor epithelium, CFFS = Clinical failure free survival; PSA = Prostate specific antigen; GS = Gleason score; TS = tumor stage; NE = No event.
Back to article page